In the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) trial involving 1,513 patients with type 2 diabetes and nephropathy, a baseline systolic blood pressure (SBP) of 140-159 mmHg was associated with a 38% greater risk of a composite renal outcome (doubling of serum creatinine, progression to end-stage renal disease (ESRD), or death) compared with those with a baseline SBP of <130 mmHg [29]. Here, AGT is linked to type 2 diabetes mellitus.